Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Health Catalyst ( (HCAT) ) has shared an announcement.
On April 24, 2026, Health Catalyst’s board decided to eliminate the Chief People Officer role as part of a broader restructuring, with current CPO Linda Llewelyn set to leave the position effective June 1, 2026 and then serve as a senior advisor from June 2 through September 1, 2026 under a planned separation and independent contractor arrangement. The separation is tied to benefits under the firm’s executive severance plan and reflects a leadership realignment amid wider cost-cutting.
Also on April 24, 2026, the board approved a workforce reduction under Project Nexus, a strategic overhaul intended to simplify the operating model and concentrate resources on high-conviction technology bets, which will cut about 9% of the global workforce and remove roughly 100 additional open positions in the U.S. and India. The initiative marks a significant step in reshaping Health Catalyst’s cost structure and organizational footprint, with further details to be provided in its next quarterly filing.
The most recent analyst rating on (HCAT) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Health Catalyst stock, see the HCAT Stock Forecast page.
Spark’s Take on HCAT Stock
According to Spark, TipRanks’ AI Analyst, HCAT is a Neutral.
The score is held down primarily by weak financial performance (widening losses and negative free cash flow) and bearish technical signals (price below key moving averages with negative MACD). Earnings-call commentary shows improving adjusted profitability but elevated churn/migration risk and limited guidance visibility, while valuation support is constrained by losses and no stated dividend.
To see Spark’s full report on HCAT stock, click here.
More about Health Catalyst
Health Catalyst, Inc. operates in the healthcare technology and data analytics industry, providing software, data warehousing, and related services to help health systems and other healthcare organizations improve clinical, financial, and operational performance. The company focuses on leveraging data and analytics-driven solutions to support value-based care, efficiency gains, and technology-enabled transformation across its client base.
Average Trading Volume: 850,954
Technical Sentiment Signal: Sell
Current Market Cap: $101.5M
See more data about HCAT stock on TipRanks’ Stock Analysis page.